Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net ...
The Clinton Herald

TO YOUR GOOD HEALTH: Surgery is prudent if conservative treatment of neuroma fails

I am a 68-year-old woman who is in relatively good health. My primary exercise is walking my dogs anywhere from 2-5 miles per ...
Optometry Advisor

Adalimumab Biosimilar Yuflyma Gets Approval for Additional Pediatric Indications

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...
The Lancet

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

Vedolizumab treatment is safer and more effective in early than in late Crohn's disease. Vedolizumab could be considered as a ...